Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

  • Saadettin KilickapEmail author
  • Sevgen Onder
  • Omer Dizdar
  • Mustafa Erman
  • Aysegul Uner
Letter to the Editor


Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.


Lung cancer ALK positive Crizotinib Neoadjuvant therapy 



This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

No conflict of interest for all authors.


  1. 1.
    Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450–1454CrossRefGoogle Scholar
  2. 2.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefGoogle Scholar
  3. 3.
    Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394CrossRefGoogle Scholar
  4. 4.
    Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski FM et al (2012) Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 30:172–178CrossRefGoogle Scholar
  5. 5.
    Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, SAKK Lung Cancer Project Group et al (2015) Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 386:1049–1056CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyHacettepe University Institute of CancerAnkaraTurkey
  2. 2.Department of PathologyHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations